跳转至内容
Merck
CN

53571-U

Ascentis® Express 90 Å F5 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 2.1 mm, HPLC Column

别名:

Core-shell (SPP) Fused Core PFP HPLC column

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
15 cm × 2.1 mm
Particle size:
2.7 μm
Matrix active group:
PFP (pentafluorophenyl) phase
Pore size:
90 Å pore size
Matrix:
Fused-Core particle platform, superficially porous particle
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Ascentis® Express F5, 2.7 μm HPLC 色谱柱, 2.7 μm particle size, L × I.D. 15 cm × 2.1 mm

material

stainless steel column

agency

suitable for USP L43

product line

Ascentis®

feature

endcapped

manufacturer/tradename

Ascentis®

packaging

1 ea of

parameter

60 °C temp. range, 600 bar max. pressure (9000 psi)

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

L × I.D.

15 cm × 2.1 mm

surface area

135 m2/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform, superficially porous particle

matrix active group

PFP (pentafluorophenyl) phase

particle size

2.7 μm

pore size

90 Å pore size

operating pH

2-8

application(s)

food and beverages

separation technique

reversed phase

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

由于存在电负性氟,Ascentis Express F5 的五氟苯基丙基固定相可提供具有缺电子苯环的稳定反相填料。除了形成 pi-pi 和温和的空间相互作用外,F5 相也通过极性相互作用保留化合物。Ascentis Express F5 可用于碱性、酸性或中性化合物,选择性与 C18 不同。

Application

  • Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
  • Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Iltaf Shah et al.
The Journal of steroid biochemistry and molecular biology, 180, 118-128 (2018-02-13)
Research shows that immunoassay techniques are not the best choice for the estimation of vitamin D in human blood samples. The main reasons are that some immunoassays are not able to distinguish between 25-OHD3 and 25-OHD2 vitamin D metabolites. Furthermore

商品

Using HybridSPE-Phospholipid, Ascentis Express, and Other LC-MS Workflow Components

Enhanced selectivity for stereoisomers and closely related compounds with alternate selectivity from C18 phases for basic, acidic, or neutral compounds

Novel sample prep technique coupled with the unique selectivity of the Ascentis Express F5 column enables a fast and simplified bioanalytical method for associated vitamin D metabolites.

实验方案

Fast and Accurate LC-MS Analysis of Vitamin D Metabolites, Using Ascentis® Express F5 HPLC Columns from Supelco®

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持